Spero Therapeutics (SPRO) Operating Leases (2019 - 2026)
Spero Therapeutics' (SPRO) quarterly Operating Leases came in at $507000.0 in Q1 2026, down 76.58% YoY from $2.2 million in Q1 2025, and down 46.01% on a QoQ basis from $939000.0 in Q4 2025.
Spero Therapeutics (SPRO) Operating Leases (2019 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 8 years of Operating Leases data on file, last reported at $507000.0 in Q1 2026.
- Quarterly Operating Leases fell 76.58% year-over-year to $507000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507000.0 (down 76.58% YoY) and the FY2025 annual result came in at $939000.0, down 63.19% from the prior year.
- Operating Leases slipped to $507000.0 in Q1 2026, from $939000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $5.7 million in Q1 2022 to a low of $507000.0 in Q1 2026.
- A 5-year average of $3.4 million and a median of $3.5 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases fell 14.06% — and 2026, when it tumbled 76.58%.
- Tracing SPRO's Operating Leases over 5 years: stood at $5.0 million in 2022, then declined by 22.84% to $3.8 million in 2023, then plunged by 33.31% to $2.6 million in 2024, then plunged by 63.19% to $939000.0 in 2025, then tumbled by 46.01% to $507000.0 in 2026.
- The last three Operating Leases figures came in at $507000.0 (Q1 2026), $939000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43,000.00 |
| Mar 31, 2026 | 507,000.00 |
| Dec 31, 2025 | 939,000.00 |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 2.88 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | 3.83 Mn |
| Sep 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 4.41 Mn |
| Mar 31, 2023 | 4.69 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 5.22 Mn |
| Jun 30, 2022 | 5.47 Mn |
| Mar 31, 2022 | 5.73 Mn |
| Dec 31, 2021 | 5.97 Mn |
| Sep 30, 2021 | 6.19 Mn |